Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $29.50.

RCUS has been the topic of several research reports. Bank of America cut their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday. HC Wainwright cut their price target on Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, Morgan Stanley dropped their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th.

Insider Activity at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.30% of the stock is owned by company insiders.

Institutional Trading of Arcus Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. R Squared Ltd acquired a new position in shares of Arcus Biosciences during the 4th quarter worth about $26,000. Point72 Hong Kong Ltd bought a new position in Arcus Biosciences during the third quarter worth about $47,000. Lazard Asset Management LLC increased its position in Arcus Biosciences by 3,321.3% during the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after buying an additional 6,078 shares during the last quarter. US Bancorp DE raised its stake in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after buying an additional 6,615 shares during the period. Finally, Quest Partners LLC lifted its position in shares of Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $11.06 on Tuesday. The company has a market capitalization of $1.01 billion, a P/E ratio of -3.51 and a beta of 0.84. Arcus Biosciences has a 52 week low of $10.63 and a 52 week high of $20.31. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The company’s 50 day moving average price is $13.92 and its two-hundred day moving average price is $15.55.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.